These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21118801)

  • 41. Anticancer effects of some novel dichloroacetophenones through the inhibition of pyruvate dehydrogenase kinase 1.
    Zhang SL; Yang Z; Hu X; Chakravarty H; Tam KY
    Eur J Pharm Sci; 2018 Oct; 123():43-55. PubMed ID: 30012506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening.
    Yang W; AbdulHameed MD; Hamza A; Zhan CG
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1629-32. PubMed ID: 22266037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting 3-phosphoinositide-dependent protein kinase 1 by N-acetyl-cysteine through activation of peroxisome proliferators activated receptor alpha in human lung cancer cells, the role of p53 and p65.
    Hann SS; Zheng F; Zhao S
    J Exp Clin Cancer Res; 2013 Jul; 32(1):43. PubMed ID: 23867003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PDK1 Mediates
    Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
    Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inverse in silico screening for identification of kinase inhibitor targets.
    Zahler S; Tietze S; Totzke F; Kubbutat M; Meijer L; Vollmar AM; Apostolakis J
    Chem Biol; 2007 Nov; 14(11):1207-14. PubMed ID: 18022559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery.
    Johnson MC; Hu Q; Lingardo L; Ferre RA; Greasley S; Yan J; Kath J; Chen P; Ermolieff J; Alton G
    J Comput Aided Mol Des; 2011 Jul; 25(7):689-98. PubMed ID: 21779981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo role of the phosphate groove of PDK1 defined by knockin mutation.
    Collins BJ; Deak M; Murray-Tait V; Storey KG; Alessi DR
    J Cell Sci; 2005 Nov; 118(Pt 21):5023-34. PubMed ID: 16219676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
    Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
    Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
    Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
    Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of transforming growth factor-beta signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein.
    Seong HA; Jung H; Choi HS; Kim KT; Ha H
    J Biol Chem; 2005 Dec; 280(52):42897-908. PubMed ID: 16251192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational design of mitochondria-targeted pyruvate dehydrogenase kinase 1 inhibitors with improved selectivity and antiproliferative activity.
    Xu B; Yu Z; Xiang S; Li Y; Zhang SL; He Y
    Eur J Med Chem; 2018 Jul; 155():275-284. PubMed ID: 29890389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays.
    Hofler A; Nichols T; Grant S; Lingardo L; Esposito EA; Gridley S; Murphy ST; Kath JC; Cronin CN; Kraus M; Alton G; Xie Z; Sutton S; Gehring M; Ermolieff J
    Anal Biochem; 2011 Jul; 414(2):179-86. PubMed ID: 21402045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of direct target engagement biomarkers for kinase-targeted therapeutics.
    Paweletz CP; Andersen JN; Pollock R; Nagashima K; Hayashi ML; Yu SU; Guo H; Bobkova EV; Xu Z; Northrup A; Blume-Jensen P; Hendrickson RC; Chi A
    PLoS One; 2011; 6(10):e26459. PubMed ID: 22039492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling.
    Kurata A; Katayama R; Watanabe T; Tsuruo T; Fujita N
    Cancer Sci; 2008 Sep; 99(9):1827-34. PubMed ID: 18616680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Master kinase PDK1 in tumorigenesis.
    Zheng N; Wei J; Wu D; Xu Y; Guo J
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188971. PubMed ID: 37640147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1.
    Fujita N; Sato S; Ishida A; Tsuruo T
    J Biol Chem; 2002 Mar; 277(12):10346-53. PubMed ID: 11779851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Roles of 3-phosphoinositide-dependent kinase 1 in the regulation of endothelial nitric-oxide synthase phosphorylation and function by heat shock protein 90.
    Wei Q; Xia Y
    J Biol Chem; 2005 May; 280(18):18081-6. PubMed ID: 15737995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
    Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia.
    Peng F; Wang JH; Fan WJ; Meng YT; Li MM; Li TT; Cui B; Wang HF; Zhao Y; An F; Guo T; Liu XF; Zhang L; Lv L; Lv DK; Xu LZ; Xie JJ; Lin WX; Lam EW; Xu J; Liu Q
    Oncogene; 2018 Feb; 37(8):1062-1074. PubMed ID: 29106390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.